methyl 2-chlorobutanoate | 149948-80-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 2-chlorobutanoate
• 英文别名: methyl 2-chlorobutyrate；α-Chlor-buttersaeure-methylester
• CAS: 149948-80-1
• 化学式: C₅H₉ClO₂
• mdl: MFCD00041451
• 分子量: 136.578
• InChiKey: BHQQXAOBIZQEGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 2-chlorobutanoate 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 2-chloro-1-butanol
  参考文献：
  名称：

  Kirrmann,A.; Druesne,F., Bulletin de la Societe Chimique de France, 1964, p. 1098 - 1103

  摘要：

  DOI：
• 作为产物：
  描述：

  丁酸甲酯 在 五氯化磷 、 氯 作用下， 生成 methyl 2-chlorobutanoate
  参考文献：
  名称：

  Griehl et al., Chemische Berichte, 1958, vol. 91, p. 1165,1169

  摘要：

  DOI：

文献信息

• [EN] HUMAN ETS-RELATED GENE (ERG) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS DE GÈNES (ERG) ASSOCIÉS À L'ETS HUMAIN UTILISÉS EN TANT QU'AGENTS THÉRAPEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2018145217A1

  公开（公告）日：2018-08-16

  This invention provides compound having a structure of Formula (I): (I) Uses of such compounds for treatment of ERG, FLI1, ETV4, or ETV1 -mediated indications, including cancer. Also provided are pharmaceutical composition and methods of treating ERG, FLI1, ETV4, or ETV1-mediated indications, including cancer. The cancer may be selected from the group consisting of: prostate cancer, Ewing's sarcoma, breast cancer or pancreatic cancer.

  这项发明提供了具有以下结构的化合物：(I)：(I)。利用这些化合物治疗ERG、FLI1、ETV4或ETV1介导的疾病的用途，包括癌症。还提供了药物组合物和治疗ERG、FLI1、ETV4或ETV1介导的疾病的方法，包括癌症。癌症可以选择自前列腺癌、尤因肉瘤、乳腺癌或胰腺癌等组中的一种。
• [EN] FUSED AZOLE-PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES D'AZOLE-PYRIMIDINES FONDUES
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004029055A1

  公开（公告）日：2004-04-08

  The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (P13K) inhibition, especially for PI3K-Ϝ inhibition and can be used for the prophylaxis and treatment of diseases associated with P13K and particularly with P13K-Ϝ activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to P13K activity in a human or animal subject.

  本发明涉及杂环嘧啶衍生物，其制备方法以及含有它们的药物制剂。本发明的杂环嘧啶衍生物对磷脂酰肌醇-3-激酶（PI3K）抑制具有增强的效力，尤其对PI3K-Ϝ抑制效果显著，可用于预防和治疗与PI3K以及特别是PI3K-Ϝ活性相关的疾病。具体而言，本发明的杂环衍生物可用于治疗和预防以下疾病：炎症和免疫调节性疾病，如哮喘、特应性皮炎、鼻炎、过敏性疾病、慢性阻塞性肺病（COPD）、脓毒性休克、关节疾病、风湿性关节炎、Graves病、癌症、心肌收缩功能障碍、心力衰竭、血栓栓塞、缺血和动脉粥样硬化。本发明的化合物还可用于肺动脉高压、肾功能衰竭、心肌肥大，以及神经退行性疾病，如帕金森病、阿尔茨海默病、糖尿病和局灶性缺血，因为这些疾病也与人类或动物主体的PI3K活性有关。
• 13C NMR, 1H NMR and IR spectra of a series of monochloroesters of aliphatic short chain carboxylic acids
  作者：Maija T. Pitkänen、Ilpo O.O. Korhonen、Jorma N.J. Korvola

  DOI：10.1016/s0040-4020(01)92425-1

  日期：1981.1

  chemical shifts for 14 isomeric monochloroesters of aliphatic carboxylic acids from propanoic acid to hexanoic acid have been determined. Comparisons are made with the literature values for methyl monochloro-octanoate isomers. Substituent effects for all positions are given. Characteristic IR absorption bands are presented and comparisons are made with regard to the isomeric structure. Connections

  已确定脂肪族羧酸的14种异构一氯代酯从丙酸到己酸的13 C化学位移。与单氯辛酸甲酯异构体的文献值进行了比较。给出了所有位置的替代作用。给出了特征性的IR吸收带，并就异构体结构进行了比较。建议在观察到的红外吸收频率趋势与对13 C化学位移的某些“异常”氯取代基效应之间建立联系。考虑了这些化合物的1 H NMR谱。
• 3-치환된 에스트라-1,3,5(10),16-테트라엔 유도체, 그의 제조방법, 이를 포함하는 약학 제제 및 의약품 제조를 위한 그의 용도
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT 바이엘 파마 악티엔게젤샤프트(520020066307)

  公开号：KR20150036319A

  公开（公告）日：2015-04-07

  본 발명은 AKR1C3 저해제 및 그의 제조방법, 질환을 치료 및/또는 예방하기 위한 그의 용도 및 또한 질환, 특히 출혈성 질환 및 자궁내막증 치료 및/또는 예방용 의약품을 제조하기 위한 그의 용도에 관한 것이다.

  本发明涉及AKR1C3抑制剂及其制备方法，以及其用于治疗和/或预防疾病的用途，特别是用于制备用于治疗和/或预防出血性疾病和子宫内膜异位症的药物的用途。
• Trichloroisocyanuric Acid Oxidation of 2-Chloro Aldehyde Acetals to 2-Chloro Acid Esters
  作者：Monica Boni、Franco Ghelfi、Ugo Maria Pagnoni、Adriano Pinetti

  DOI：10.1246/bcsj.67.156

  日期：1994.1

  2-Chloro acid methyl esters were prepared in good yields treating 2-chloro aldehyde dimethyl acetals with trichloroisocyanuric acid in DMF. Aldehyde dimethyl acetals with the 2-halogen on a tertiary carbon atom were poorly reactive and could be oxidized effeciently only after their transformation into 1,3-dioxolanes.

  2-氯酸甲基酯通过在DMF中用三氯异氰尿酸处理2-氯醛二甲基缩醛制备，产率良好。含有2-卤素的醛二甲基缩醛在三级碳原子上的反应活性较差，仅在转化为1,3-二氧杂环戊烷后才可有效氧化。

表征谱图